1. Home
  2. CRWD vs JNJ Comparison

CRWD vs JNJ Comparison

Compare CRWD & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CrowdStrike Holdings Inc.

CRWD

CrowdStrike Holdings Inc.

HOLD

Current Price

$675.88

Market Cap

165.5B

Sector

Technology

ML Signal

HOLD

Logo Johnson & Johnson

JNJ

Johnson & Johnson

HOLD

Current Price

$232.40

Market Cap

542.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRWD
JNJ
Founded
2011
1886
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.5B
542.4B
IPO Year
2019
2003

Fundamental Metrics

Financial Performance
Metric
CRWD
JNJ
Price
$675.88
$232.40
Analyst Decision
Buy
Buy
Analyst Count
48
20
Target Price
$507.00
$238.20
AVG Volume (30 Days)
3.5M
5.9M
Earning Date
06-02-2026
04-14-2026
Dividend Yield
N/A
2.36%
EPS Growth
N/A
90.50
EPS
0.11
2.14
Revenue
$4,812,005,000.00
N/A
Revenue This Year
$24.85
$6.63
Revenue Next Year
$21.40
$7.43
P/E Ratio
$6,543.36
$106.65
Revenue Growth
21.71
N/A
52 Week Low
$342.72
$149.04
52 Week High
$785.66
$251.71

Technical Indicators

Market Signals
Indicator
CRWD
JNJ
Relative Strength Index (RSI) 59.78 57.14
Support Level $477.12 $222.07
Resistance Level N/A $235.50
Average True Range (ATR) 33.86 3.84
MACD 0.09 0.26
Stochastic Oscillator 46.13 83.66

Price Performance

Historical Comparison
CRWD
JNJ

About CRWD CrowdStrike Holdings Inc.

CrowdStrike is a cloud-native cybersecurity company specializing in security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform, which provides enterprises with a unified view to detect and respond to security threats across their IT infrastructure. The Austin, Texas-based firm was founded in 2011 and went public in 2019.

About JNJ Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

Share on Social Networks: